Slide #1 image
Slide #1 image
Slide #1 image
The Center of Genetic Engineering and Biotechnology (CIGB) is pleased to announce the International Workshop: “Emerging Targeted Therapies in Cancer & Autoimmunity” which will be held at the Iberostar Laguna Azul Hotel, Varadero, Cuba, from April 21 to April 24, 2016.

The four-day event will bring together basic scientists, medicinal chemists, pharmacologists, biotechnologists, clinical investigators, and other allied professionals from around the world, interested in the fields of disease pathogenesis and new targeted therapies development for Cancer and for Autoimmune Disorders. The meeting will be an excellent opportunity to expose the translational nature of modern biomedical and pharmaceutical research.

One of the key objectives of the 2016 Symposium will be to arm delegates with the necessary tools that will enable them to make a difference, implement and take actions at all levels, in global fight against cancer or autoimmunity diseases.

Mark your calendars now and stay tuned for more information.
Information on these and other International Meetings organized by the CIGB Direction of Biomedical Research for 2015 – 2016


Scientific Program

Cancer and Autoimmunity Varadero 2016 will cover the following topics:
• Molecular oncology • Mechanisms of autoimmune-related pathologies
• Tumor immunology • Regulatory T cells and autoimmunity
• Cancer Immunotherapy • Inflammasome and epigenetics
• Clinical trials • Pharmacological strategies for autoimmune diseases

The Workshop Main Topics will be presented in separate parallel sessions, except for the Opening Session.

General Program

Thursday, April 21st

• 8:00 h - Transfer from Havana to Iberostar Laguna Azul Hotel in Varadero
• 11:00 - 12:30 h - Arrival and Registration
• 17:30 - 18:30 Room 1 OPENING SESSION
• 18:30 - Dinner at the Buffet Restaurant 

Friday, April 22nd
• 08:45 - 13:15 h Room 1 - CANCER BIOLOGY AND NOVEL TARGETS
• 13:15 - 14:45 h Lunch
• 15:00 - 17:00 Room 1 - Posters
Saturday, April 23rd
• 08:45 - 10:35 h Room 1 - ANGIOGENESIS
• 10:50 - 13:15 h Room 1 - IMMUNOTHERAPY

• 13:15 - 14:45 h Lunch
Sunday, April 23rd
• 08:45 - 10:35 h Room 2 - NEUROONCOLOGY

• 16:00 h Return to Havana



During the last years it has been a practice that Invited Speakers register online. It is not mandatory, but rather an altruistic personal contribution to sponsor the participation of Delegates that otherwise would not have the necessary funds to attend the meeting. We thank in advance all Invited Speakers for registering online.

Speakers for the Cancer Symposium:
<%-- --%> <%-- --%> <%-- --%> <%-- --%> <%-- --%> <%----%> <%----%> <%----%>
Speaker Title Institution Country
Rauscher Frank J. Rauscher, III, PhD Epigenetic reprogramming of cancer cells: targeting metastatic and dormant cancer cell phenotypes to effect lasting cures Deputy Director, Wistar Institute Cancer Center USA
Kerbel Robert Kerbel, PhD Experimental therapeutics investigated in preclinical models of early or late stage metastatic disease Professor, University of Toronto Canada
Pamela Stanley, PhD Roles for Glycans in Cancer and Notch Signaling. Albert Einstein College of Medicine USA
Buchmann Michael Bachmann, PhD UniTARG, a novel modular platform technology allowing to combine BiTE and CAR technology for retargeting of tumor cells Director Institute of Radiopharmaceutical Cancer Research, Head Radioimmunology Helmholtz-Zentrum Dresden Germany
Ott Patrick Ott, MD, PhD PD-1/PD-L1 inhibition as a novel treatment strategy for cancer Clinical Director, Melanoma Disease Center and Center for Immuno-Oncology Dana-Farber Cancer Institute USA
Ebos John M.L Ebos, PhD Drug resistance in the era of stromal-targeted therapy: Lessons from antiangiogenic inhibitors. Department of Cancer Genetics, Department of Medicine Roswell Park Cancer Institute. USA
Boden Katherine LB Borden, PhD. Molecular targeting followed by Drug Resistance: The story the eukaryotic translation initiation factor eIF4E in leukemia Institute for Research in Immunology and Cancer University of Montreal   Canada
Martin Martin J. van den Bent, MD, PhD Brain Tumor Center at Erasmus MC Cancer Center, Rotterdam Netherlands
Janetzki Sylvia Janetzki, PhD Efficient immune monitoring in cancer immunotherapy trials using Elispot. University Medical Center of the Johannes Gutenberg-University Germany
Rak Janusz Rak, MD, PhD Oncogenic modifiers of exosomal communication within the vascular tumour microenvironment - therapeutic and biomarker implications Research Institute of the McGill University Health Centre Canada
Angelo Corti, PhD Peptide-based vehicles for tumor vascular targeting with cytokines Università Vita e Salute San Raffaele, Milan Italy
Gainza Eusebio Gainza, PhD. Micro-nanoformulations for cancer therapy and diagnosis Biopraxis Research AIE Praxis Pharmaceutical Spain
Olagnier David Olagnier, PhD Modulating the Nrf2 transcription factor to potentiate oncolytic virotherapy in cancer Lady Davis Institute - McGill University Canada
Verheul Henk Verheul, PhD New developments in early clinical trials from targeted therapies to vaccination strategies VU University Medical Center, Inmunovo, Amsterdam Ned
Romero Pedro Romero, PhD. Recent Progress in Immunotherapy of Cancer Ludwig Center for Cancer Research, University of Lausanne Switzerland
Carine Carine Pecqueux, M.D. The clinical perspective of translational multimodal therapeutic approaches to advanced urological tumors Heidelberg University Hospital Germany
Jonasch Eric Jonasch, MD Antiangiogenic Therapy in renal cell carcinoma. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center USA
Bodo Bodo Lippitz, PhD Unpredicted Cytokine Patterns in Cancer Patients Bupa Cromwell Hospital UK
Rabadan Raul Rabadan, Prof. Geometric approaches to cancer evolution. Department of Systems Biology, Columbia University College of Physicians and Surgeons USA
jenkins Richard O. Jenkins, Prof. Anticancer drug cytotoxicity assessed using controllable HELA TET-ON/HCYP1 cell lines. Head of Research & Innovation, Faculty of Health & Life Sciences De Montfort University, Leicester UK
Daniel80 Daniel Bachiller, PhD. Genomic modification of immune system cells for the treatment of AIDS CSIC, FISIB, Fundación de Investigaciones Sanitarias de las Islas Baleares Spain
Bachvarov Dimcho Bachvarov, PhD. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells Département de médecine moleculaire, Université Laval Canada
natasha Natasha Frank, MD ABCB5 controls colorectal cancer apoptosis resistance. Brigham And Women's Hospital DF-Harvard Cancer Center USA
Roberto Herrera, Dr. It is important to achieve Gross Total Resection of Brain Gliomas? Contribution of Intraoperative MRI (REMAIN), to do this. Clínica Adventista Belgrano. Buenos Aires.  Argentina
Korneluk Robert Korneluk, Prof. Combination of IAP antagonism and immune checkpoint blockade to treat cancer. Senior Scientist, CHEO Research Institute Distinguished Professor, Faculty of Medicine, University of Ottawa   Canada
Jose Luis Ledesma, Dr. Image Guidance in Glioma Surgery Children Hospital of Buenos Aires Argentina
 Licea Alexei Fedórovish Licea Navarro, PhD The Use of Single Domain Shark Antibodies for Cancer Therapy Experimental and Applied Biology Division, CICESE Mexico
 Pak Vladimir Pak, PhD. Alpha-fetoprotein+toxin complex as cancer immunotherapy. Freelance researcher, Toronto   Canada
Sylvia Sylvia Janetzki , PhD   University Medical Center of the Johannes Gutenberg-University Germany
Melchor80 Melchor Alvarez de Mon, Prof. Therapy and Diagnostic of Glioma (THERAGLIO) Hospital Universitario Príncipe de Asturias. Facultad de Medicina Universidad de Alcalá. Spain
beug Shawn Beug, PhD. Potentiation of the anti-Cancer Effects of SMAC Mimetics In Combination With Immunostimulants CHEO Research Institute Distinguished Professor, Faculty of Medicine, University of Ottawa   Canada


Speakers for the Autoimmunity Symposium:

<%-- --%> <%-- --%> <%-- --%> <%-- --%>
Speaker Title Institution Country
 Miller Stephen D. Miller, PhD Targeting the Immune Checkpoint Inhibitor B7-H4 for the Therapy of Autoimmunity and Cancer  Director-Interdepartmental Immunobiology Center Northwestern University Medical School USA
Vanda A. Lennon, MD, PhD Neurological Autoimmunity: Immunopathogenesis and Autoantibody Profiles Aiding Diagnosis of Related Systemic Cancers. Dorothy A. Adair Professor, Dep. of Lab. Medicine and Pathology, Neurology and Immunology Mayo Clinic College of Medicine USA
Leis E. Richard Stanley, PhD Studies of the CSF-1 receptor reveal therapeutic targets for tumor progression, leukodystrophies and chronic inflammatory and autoimmune diseases  Department of Developmental and Molecular Biology, Albert Einstein College of Medicine USA
Willem van Eden, , MD, PhD Towards an HSP70 loaded tolDC cellular therapy for chronic inflammatory diseases. Professor, Universiteit Utrecht NL
khan Muhammad Asim Khan, Dr. Emerging Therapies in Ankylosing Spondylitis, Psoriasis and Psoriatic Arthritis Case Western Reserve University, MetroHealth Medical Center USA
bonnan Mickael Bonnan, MD Intrathecal therapy in multiple sclerosis? Review of evidence supporting the need of future trials. Service de neurologie, Centre hospitalier de Pau  france
kamal Kamal D. Moudgil, MD, PhD A novel peptide-directed cytokine therapy for autoimmune arthritis. Department of Microbiology and Immunology University of Maryland School of Medicine USA
Leis Jose F. Leis, M.D., PhD Impact of targeted therapies on CLL, autoimmune hemolytic anemia, and other associated autoimmune disorders Associate Professor of Medicine Mayo Clinic Cancer Center USA
francisco Francisco Javier Quintana, PhD Regulation of CNS inflammation Associate Scientist, Brigham and Women's Hospital, Harvard Medical School USA
pagliari Danilo Pagliari, MD The link between gastrointestinal 'immunological niche' and xenobiotics in the pathogenesis of inflammatory bowel pathologies Associate Scientist, Department of Internal Medicine, Catholic University of the Sacred Heart, Rome
 markus Markus Frank, PhD Stem cell-mediated immunomodulation in normal skin and skin-associated malignancy Brigham And Women's Hospital DF-Harvard Cancer Center USA

<%-- --%>
Silver CIGB ICGEB iberostar TWAS
Seppic   WCR
bcfarma Praxis


Call for Sponsorship:

We are pleased to offer companies and organizations the opportunity to be corporate sponsors for the International Meeting Cancer Varadero 2016 , which will be held in Varadero from April 21 to April 24, 2016.

In this meeting we will discussing about cutting-edge advances in the basic, preclinical and clinical topics, as well as regulatory aspects for the development of new therapeutic candidates targeting to tumor and autoimmune disorders. This four-day event will be an excellent opportunity to promote the translational nature of modern biomedical and pharmaceutical research, with both scientists and clinicians associated with either drug discovery research or patient care. It will bring together leading clinicians, medicinal chemists, pharmacologists, biotechnologists, and other allied professionals to discuss and present the latest important developments in these fields. The symposium promises to provide delegates participating with more opportunities to interact with other experts from around the world.

Sponsors are very important to the Workshop, and the Organizing Committee ensures that their contribution is well recognized. We hope you will be part of the International Meeting Cancer Varadero 2016!

Contacting us: For any other questions or requests, please email the Organizing Committee.